The RSV vaccination eligibility age has been lowered from 60 years to 50 years according to an update on the CDC website.

The Food and Drug Administration has approved three vaccines for RSV — GSK's GSK.L Arexvy, Moderna's MRNA.O mRESVIA and ...

The expanded recommendation is good news for Moderna, Pfizer, and GSK, which all sell RSV vaccines for older adults. Moderna ...

The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50 instead of 60.

The votes on vaccine recommendations are the first move by the panel after Health and Human Services Secretary Robert F.

Robert F. Kennedy Jr. had fired all 17 members of a key vaccine panel. Now his new panel recommended a new infant RSV vaccine ...

The US FDA approved an RSV vaccine called Arexvy. How effective is it, when will it be available, and who can take it? CNN Medical Analyst Dr. Leana Wen explains.

The Food and Drug Administration on Wednesday approved Arexvy, the world's first respiratory syncytial virus (RSV) vaccine — a scientific breakthrough 60 years in the making.

RSV vaccines by Pfizer and GlaxoSmithKline for people aged 60 years and older were approved by the FDA earlier this year and have shown to be up to 94% effective at preventing severe illness.

The CDC already recommends the RSV shot for all adults 75 and older and for people 60 and older who have health conditions that increase their risk of severe RSV.

Failure to recognize and resolve problems in an honest and evidence-based manner is the root cause of increasing vaccine ...